Publications by authors named "Pierre-Marie Morice"
Poly(ADP-ribose) polymerase inhibitors (PARPi) have been shown to improve progression-free survival, particularly in homologous recombination-deficient ovarian cancers. Identifying patients eligible for PARPi is currently based on next-generation sequencing, but the persistence of genomic scars in tumors after restoration of homologous recombination (HR) or epigenetic changes can be a limitation. Functional assays could thus be used to improve this profiling and faithfully identify homologous recombination-deficient tumors.
View Article and Find Full Text PDFSchizophrenia is a chronic mental illness, with a prevalence of about 1%. The symptoms are classified in three categories: positive symptoms, negative symptoms and deficits in cognitive function. Regarding the pharmacological treatment, current antipsychotics mainly improve positive symptoms while negative and cognitive symptoms remain inadequately treated.
View Article and Find Full Text PDFAcute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO's pharmacovigilance database.
Blood Cancer J
October 2024
Article Synopsis
- Ovarian cancer, a leading cause of gynecological cancer deaths, often becomes resistant to chemotherapy, highlighting the urgency for new treatment approaches and predictive biomarkers.
- The OVAREX study investigates the feasibility of creating patient-derived tumor models (like PDX, PDTO, and ADS) to predict clinical outcomes for ovarian cancer patients undergoing treatment.
- This research aims to validate the predictive capabilities of these models by comparing their responses to treatments with actual patient outcomes, potentially enhancing clinical decision-making.
Arterial hypertension associated with PARPi: A meta-analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study.
Fundam Clin Pharmacol
August 2024
Article Synopsis
- This study reviews the risk of arterial hypertension in patients using poly (ADP-ribose) polymerase inhibitors (PARPi) based on data from randomized controlled trials (RCTs).
- In analyzing 41 RCTs with over 15,000 patients, it was found that while olaparib was associated with a lower hypertension risk compared to placebo, niraparib significantly increased the risk of hypertension. The incidence was reported at about 19.87%.
- The findings highlight the importance of monitoring for hypertension when using niraparib to ensure the therapeutic benefits are maintained, especially given that 66% of hypertension cases in real life were serious.
Article Synopsis
- Hip fractures primarily impact older adults, leading to increased health complications and risks, prompting a review of non-steroidal anti-inflammatory drugs (NSAIDs) during their surgical recovery.
- The systematic review followed PRISMA guidelines, analyzing various studies on NSAIDs' effectiveness and safety in post-operative outcomes like pain control and complications after hip fracture surgery.
- Although some studies supported NSAIDs for pain management, findings on safety were inconsistent, indicating a need for more research to clarify the overall benefits and risks of using NSAIDs in these patients.*
Background: In the era of personalized medicine, the establishment of preclinical models of cancer that faithfully recapitulate original tumors is essential to potentially guide clinical decisions.
Methods: We established 7 models [4 cell lines, 2 Patient-Derived Tumor Organoids (PDTO) and 1 Patient-Derived Xenograft (PDX)], all derived from the same Ovarian Clear Cell Carcinoma (OCCC). To determine the relevance of each of these models, comprehensive characterization was performed based on morphological, histological, and transcriptomic analyses as well as on the evaluation of their response to the treatments received by the patient.
Article Synopsis
- The study aimed to evaluate the incidence of atrial fibrillation (AF) linked to 19 anticancer drugs used alone in clinical trials, focusing on how common AF is among cancer patients receiving these treatments.
- Researchers analyzed 191 clinical trials involving 16 anticancer drugs and found that AF rates varied from 0.26 to 4.92 cases per 100 person-years, with the highest rates associated with ibrutinib, clofarabine, and ponatinib.
- The findings highlight that AF is a significant concern in patients undergoing treatment with these drugs, suggesting the need for better monitoring procedures in clinical trials for drugs known to cause higher AF rates.
Article Synopsis
- The study aims to create a new automated method for quantifying protein biomarkers in high-grade serous ovarian tumors (HGSOC), focusing on a more universal approach rather than arbitrary thresholds.
- It analyzes a small group of 25 HGSOC cases, calibrating algorithms with expert Stereology analyses to assess immunohistochemical staining in tumor samples.
- Results indicate a strong correlation between expert assessments and automated image processing, which enhanced understanding of staining heterogeneity and could improve pathologists' decision-making in treatment options.
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Clin Cancer Res
December 2022
Article Synopsis
- The study analyzed the incidence and characteristics of therapy-related myeloid neoplasms (t-MN) in ovarian cancer patients treated with PARP inhibitors (PARPi) at a French cancer center.
- Out of 373 patients with ovarian cancer under PARPi treatment, 3.5% developed t-MN, showing longer treatment duration and more severe cytopenias compared to those without t-MN.
- Key findings indicated a high frequency of BRCA1/2 mutations in t-MN patients exposed to PARPi, and the presence of complex karyotypes linked to poor overall survival, highlighting the need for early detection of this complication.
Article Synopsis
- - Transverse myelitis (TM) has been linked to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine, but the relationship with other vaccines like Pfizer, Moderna, AstraZeneca, and Novavax is unclear, prompting this study to explore these associations.
- - The research analyzed safety reports from the WHO's VigiBase, focusing on TM cases occurring within 28 days after receiving any FDA or EMA approved SARS-CoV-2 vaccine between December 2020 and March 2022.
- - Results indicated a significant association between both mRNA-based and vector-based vaccines and TM, yet TM is still rare (0.28 cases per million doses), suggesting the overall benefits of vaccination outweigh the risks
Article Synopsis
- * A disproportionality analysis revealed that out of over 1.3 million reports involving ASMs, a small percentage (2.91‰) were related to RTAs, with certain ASMs (like cannabis) showing a stronger association with these accidents.
- * The findings suggest that some ASMs may significantly increase the risk of RTAs, highlighting the need for caution in prescribing these medications to patients who may be at a higher risk for driving-related incidents.
This cross-sectional study uses pharmacovigilance data to investigate the occurrence of pancytopenia among patients with cancer treated with poly(adenosine diphosphate–ribose) polymerase inhibitors and examines the clinical features of pancytopenia related to these drugs.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to investigate the cardiovascular immune-related adverse events (irAEs) linked to immune checkpoint inhibitors (ICIs) in cancer patients, as the risks and incidence of these events were not well understood.
- Researchers reviewed randomized clinical trials (RCTs) to analyze data on various cardiovascular adverse events (CVAEs), finding that ICI exposure significantly increased the risk of six specific CV irAEs, including myocarditis and dyslipidemia.
- The incidence of these cardiovascular events varied between 3.2 to 19.3 per 1000 patients, emphasizing the need for awareness among healthcare providers regarding these potential risks when using ICIs.
Article Synopsis
- - Ovarian cancer (OC) has a high mortality rate due to late diagnosis and low chemotherapy effectiveness, with a 5-year survival rate under 40%.
- - The long non-coding RNA UCA1 is overexpressed in chemoresistant OC cells, correlating with poor patient prognosis, and its downregulation can make these cells more sensitive to cisplatin treatment.
- - The study reveals that UCA1 interacts with miR-27a-5p to regulate UBE2N, leading to increased levels of the pro-apoptotic protein BIM, suggesting that targeting UBE2N could be a new approach to combat chemoresistance in OC.
Within the past few years, poly (ADP-ribose) polymerase inhibitors (PARPi) have been added to the standard of care for cancer patients, mainly for those exhibiting specific genomic alterations in the homologous recombination (HR) pathway. Until now, patients who are eligible to receive PARPi have been identified using next-generation sequencing (NGS) of gene panels. However, NGS analyses do have some limitations, with a subset of patients with negative NGS-based results can exhibit a clinical benefit, responding positively to PARPi, despite the failure to detect dynamic and predictive biomarkers such as mutated BRCA1/2 genes.
View Article and Find Full Text PDFBackground: Poly(ADP-ribose) polymerase (PARP) inhibitors have shown efficacy and acceptable safety in a range of neoplasms, particularly in ovarian cancers. However, some concerns have emerged regarding rare and delayed adverse events including cases of myelodysplastic syndrome and acute myeloid leukaemia, for which data are scarce. The aim of this study was to estimate the risk of myelodysplastic syndrome and acute myeloid leukaemia related to PARP inhibitors, via a systematic review and safety meta-analysis, and to describe clinical features of PARP inhibitor-related myelodysplastic syndrome and acute myeloid leukaemia cases reported in WHO's pharmacovigilance database (VigiBase).
View Article and Find Full Text PDFHazardous Drug Diversion of Valproate from a General Practitioner to his Patient's Dog.
Drug Saf Case Rep
December 2017
Article Synopsis
- General practitioners play a critical role in safe medication practices, as many patients experience unintended medication discrepancies when admitted to the hospital.
- A case study highlights a 66-year-old man who was accidentally given valproate, intended for his epileptic dog, during a hospital stay for surgery.
- The article stresses the importance of collaboration among healthcare providers to prevent prescription errors and reduce the risk of negative drug reactions.